United Therapeutics Corporation (UTHR) Earns News Impact Rating of 0.13
News coverage about United Therapeutics Corporation (NASDAQ:UTHR) has trended somewhat positive on Friday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. United Therapeutics Corporation earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 69 out of 100, meaning that recent news coverage is likely to have an effect on the company’s share price in the near future.
These are some of the media headlines that may have effected Accern Sentiment’s analysis:
- Insider Selling: United Therapeutics Corporation (UTHR) CEO Sells 1,234 Shares of Stock (americanbankingnews.com)
- United Therapeutics Reaches Analyst Target Price – Nasdaq (nasdaq.com)
- Insider Activity – United Therapeutics Corporation (NASDAQ:UTHR) (highlightpress.com)
- Share Performance in View for United Therapeutics Corporation (NASDAQ:UTHR) – Jonesboro Recorder (jonesbororecorder.com)
- Insider Selling: United Therapeutics Corporation (UTHR) CEO Sells 1,238 Shares of Stock (americanbankingnews.com)
Shares of United Therapeutics Corporation (NASDAQ:UTHR) traded down 0.08% on Friday, hitting $131.59. The company had a trading volume of 1,195,642 shares. The company has a 50-day moving average of $124.68 and a 200 day moving average of $138.61. United Therapeutics Corporation has a 12 month low of $97.52 and a 12 month high of $169.89. The stock has a market cap of $5.93 billion, a PE ratio of 9.24 and a beta of 1.56.
United Therapeutics Corporation (NASDAQ:UTHR) last issued its earnings results on Wednesday, April 26th. The biotechnology company reported $3.89 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.12 by $0.77. The firm had revenue of $370.50 million during the quarter, compared to analysts’ expectations of $399.59 million. United Therapeutics Corporation had a net margin of 41.04% and a return on equity of 34.74%. The firm’s revenue for the quarter was up .4% compared to the same quarter last year. During the same period last year, the firm posted $3.02 earnings per share. Analysts anticipate that United Therapeutics Corporation will post $14.42 EPS for the current fiscal year.
A number of equities research analysts have weighed in on UTHR shares. Leerink Swann lifted their price objective on United Therapeutics Corporation from $127.00 to $148.00 and gave the company a “market perform” rating in a report on Thursday, February 23rd. Ladenburg Thalmann Financial Services downgraded shares of United Therapeutics Corporation from a “buy” rating to a “neutral” rating and set a $145.00 price target for the company. in a research report on Thursday, February 23rd. Zacks Investment Research downgraded shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Monday, February 27th. Wedbush reiterated an “outperform” rating and set a $229.00 price target on shares of United Therapeutics Corporation in a research report on Monday, February 27th. Finally, Jefferies Group LLC downgraded shares of United Therapeutics Corporation from a “hold” rating to an “underperform” rating and reduced their price target for the company from $149.47 to $116.00 in a research report on Monday, March 6th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $137.09.
In related news, CEO Martine A. Rothblatt sold 1,230 shares of the firm’s stock in a transaction that occurred on Thursday, March 30th. The shares were sold at an average price of $134.56, for a total transaction of $165,508.80. Following the completion of the sale, the chief executive officer now directly owns 1,370 shares in the company, valued at $184,347.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Martine A. Rothblatt sold 1,258 shares of the firm’s stock in a transaction that occurred on Thursday, April 13th. The stock was sold at an average price of $122.12, for a total transaction of $153,626.96. Following the sale, the chief executive officer now owns 1,398 shares of the company’s stock, valued at $170,723.76. The disclosure for this sale can be found here. Insiders have sold 16,273 shares of company stock valued at $2,030,260 over the last 90 days. 7.50% of the stock is currently owned by insiders.
United Therapeutics Corporation Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.